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Axillary involvement is an important 
prognostic factor for breast cancer. 
This prospective study investigated 
the accuracy of preoperative tools in 
axillary staging; percutaneous needle 
biopsies, diffusion weighted imaging 
(DWI) and contrast-enhanced ultra-
sound (CEUS). This thesis revealed 
that core biopsy is more accurate 
than fine needle aspiration and it 
reduces the need for sentinel lymph 
node biopsy. Moreover, DWI and 
CEUS-guided biopsy, have moderate 
diagnostic properties but more stud-
ies will be needed before introducing 
these methods into routine clinical 
practice.
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ABSTRACT 
 
Breast cancer is the most common cancer among women in the industrial countries and the 
leading cause of cancer-related deaths in working-age women. Every ninth woman in 
Finland will be diagnosed with breast cancer during her life-time. Axillary involvement has 
been the single most important prognostic factor and previously axillary evacuation was 
the golden standard with which to stage axilla. After the development of sentinel lymph 
node biopsy and adjuvant treatments for breast cancer (radiation-, chemotherapy and 
hormonal treatments) the need for radical axillary evacuation has decreased. Today axillary 
evacuation is performed only in cases where axillary involvement is proven in the sentinel 
lymph node biopsy or in preoperative percutaneous axillary biopsies. In axillary evacuation 
at least 10 lymph nodes are removed from the axillary fat and the procedure can cause 
severe side effects, such as lymphedema, pain or traction, in many women. Axillary staging 
is evolving rapidly and it is also a topic of intense research. The goal has been to find less 
invasive procedures to stage the axilla in order to prevent any unnecessary reduction in the 
quality of life after breast cancer surgery. 
The aim of this thesis was to study the diagnostic performance and feasibility of 
preoperative imaging and needle-biopsies in axillary staging in newly diagnosed patients 
with breast cancer. Between the years 2011 to 2014 newly diagnosed breast cancer patients 
were recruited into this study in Kuopio University Hospital. The first publication (n = 182) 
compared the accuracy of core-needle sampling and fine-needle aspiration in axillary 
lymph node biopsy. The second study (n = 54) investigated the diagnostic performance and 
feasibility of exploiting magnetic resonance diffusion weighted imaging in the preoperative 
staging of axilla. Finally, the third study (n = 54) evaluated the use of contrast-enhanced 
ultrasound to assist in guiding axillary core biopsy. In all of the studies, the imaging and 
needle biopsy results were compared to the final histopathology. 
The conclusion of the first study was that core biopsy is more accurate and reliable than 
fine-needle aspiration in demonstrating the metastases in the axillary lymph nodes 
(sensitivity 83 % vs 75 %, specificity for both 100 %). The second study revealed that the 
diffusion weighted imaging findings were clearly associated with axillary involvement. 
Nevertheless, the diagnostic values remained moderate and thus either needle biopsies or 
the sentinel procedure cannot be omitted. Finally, the third study demonstrated that the 
sentinel lymph node biopsy with ultrasound contrast is feasible and it recognises the 
majority of metastases in US node negative axillae. Nevertheless, some patients with 
axillary macrometastases were not identified. Hence the procedure in its present form 
cannot be recommended for use in routine clinical practice, although it may be beneficial in 
certain, selected patient populations. 
National Library of Medical Classification: WP 870, WP 815, WB 379 
Medical Subject Headings: Breast Neoplasms; Ultrasonography, Mammary; Axilla; Biopsy, Needle; Contrast 
Media/diagnostic use; Diffusion Magnetic Resonance Imaging; Sentinel Lymph Node Biopsy; Axilla/surgery; 
Neoplasm Staging 
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TIIVISTELMÄ 
 
Rintasyöpä on teollisuusmaiden yleisin naisten syöpä ja aiheuttaa edelleen eniten 
työikäisten naisten syöpäkuolemia. Suomessa noin joka 9. nainen saa elämänsä aikana 
rintasyövän. Kainalolevinneisyyttä on pidetty rintasyövän tärkeimpänä yksittäisenä 
ennustetekijänä ja sitä selvitettiin aiemmin kainaloevakuaatiolla eli kainalon 
imusolmukkeiden tyhjennyksellä. Vartijaimusolmuketutkimuksen ja rintasyövän 
liitännäishoitojen (säde-, solunsalpaaja- ja hormonihoitojen) kehittyessä tarve radikaalille 
kainaloevakuaatiolle on vähentynyt. Nykyisin vain niille, joilla todetaan metastasointi 
leikkausta edeltävästi kuvantaohjatuissa neulanäytteissä tai vartijaimusolmuke-
tutkimuksessa, tehdään kainalon imusolmukkeiden tyhjennys. Evakuaatiossa tyhjennetään 
vähintään 10 imusolmuketta kainalosta, mistä voi seurata merkittävälle osalle potilaista 
käden turvotus-, kipu- ja kiristysoireita. Kainalolevinneisyyden selvittäminen on 
kansainvälisesti kiivaan tutkimuksen ja muutosten kohteena. Pyrkimyksenä on löytää 
vähemmän kajoavia menetelmiä, jotta potilaiden myöhempi elämänlaatu ei kärsisi 
kainalolevinneisyyden selvittämisen vuoksi. 
Tämän väitöskirjatutkimuksen tarkoitus oli selvittää leikkausta edeltävien kuvantamis- 
ja näytteenottomenetelmien diagnostista osuvuutta ja käyttökelpoisuutta rintasyövän 
kainalolevinneisyyden selvittelyssä. Tutkimuksiin rekrytoitiin Kuopion yliopistollisen 
sairaalan uusia rintasyöpäpotilaita vuosina 2011 - 2014. Ensimmäisessä osatyössä (n = 182) 
tehtiin vertaileva tutkimus kainalon imusolmukkeiden ohut- ja paksuneulanäytteistä. 
Toisessa osatyössä (n = 54) tutkittiin magneettidiffuusiokuvauksen osuvuutta ja tarkkuutta 
havaita kainalon metastasointi. Kolmannessa osatyössä (n = 54) arvioitiin 
ultraäänivarjoaineella suoritetun vartijaimusolmuketutkimuksen ja imusolmukkeen 
paksuneulanäytteenoton luotettavuutta ja käyttökelpoisuutta. Kaikissa osatöissä 
kuvantamis- ja neulanäytelöydöksiä verrattiin lopulliseen leikkaustulokseen. 
Ensimmäisen osatyön tulokset osoittivat, että kainaloimusolmukkeiden näytteenotossa 
paksuneulanäyte on herkempi ja luotettavampi menetelmä verrattuna 
ohutneulanäytteeseen (herkkyys 83 % vs 75 %, tarkkuus molemmilla 100 %). Toisessa 
osatyössä havaittiin, että magneettidiffuusiokuvauksen löydökset liittyvät vahvasti 
kainalometastasointiin. Menetelmän herkkyys ja erityisesti tarkkuus kuitenkin jäävät 
kohtalaiselle tasolle, eikä neulanäytteitä tai vartijaimusolmuketutkimusta pystytä 
korvaamaan tällä menetelmällä. Kolmannessa osatyössä havaittiin, että vartijatutkimus 
voidaan suorittaa luotettavasti myös ultraäänivarjoaineella ja tutkimus yhdessä 
neulanäytteen kanssa löytää ultraäänessä normaaleiksi tulkittavista kainaloista merkittävän 
osan etäpesäkkeistä. Osa sairaista imusolmukkeista kuitenkin tulkittiin menetelmällä 
normaaleiksi, minkä vuoksi menetelmä ei tässä vaiheessa sovi rutiininomaiseen käyttöön 
kliinisessä työssä, mutta soveltuu tehtäväksi rajatuille potilasryhmille. 
Yleinen Suomalainen asiasanasto: rintasyöpä; levinneisyys; imusolmukkeet; ultraäänitutkimus; biopsia; 
varjoainetutkimus; magneettitutkimus; diffuusiokuvaus 
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 1 Introduction 
Breast cancer is the most common cancer among women and the leading global cause of 
cancer related deaths (1). Regional axillary metastases have been found to be the single 
most important prognostic factor for breast cancer, hence necessitating axillary staging 
(2,3). The history of breast cancer treatment starts with the surgical options dating from 19th 
century i.e. radical mastectomy (removal of the breast, chest muscles and axillary fat); these 
have evolved to much less radical approaches with the introduction of partial resection and 
oncoplastic surgery with additional treatments (4,5). The survival rate after diagnosis of 
breast cancer has increased remarkably in conjunction with the advances in chemo-, 
hormonal- (6) and radiotherapy (7). In addition, there are survival benefits attributable to 
breast cancer screening programs which are in place in the industrialized countries (8-10). 
The overall benefit of population based screening programmes has been much debated and 
citicized due to possible overdiagnosis, although there is a lack of evidence based data to 
support these criticisms  (11). The cancers found in screening are smaller than cancers 
exhibiting clinical symptoms and they tend to have less axillary positivity, leading to better 
survival prospects. Nevertheless, some of the survival benefits may be due to the different 
molecular subtypes of the screening detected cancers (12).  
Since there has been a desire to conduct less radical treatments of the breast i.e. breast 
conserving surgery, the axillary evacuation has become less popular over the last 20 years 
after the introduction of sentinel lymph node (SLN) labelling and removal (13,14). Axillary 
ultrasound (US) has been used for the evaluation of metastatic lymph nodes (LNs) since the 
1980’s (15,16) and image-guided percutaneous needle biopsies became more popular in the 
1990’s (17,18). 
Recently, there has been a debate about the optimal treatment of axillary metastases in 
those patients having smaller breast tumours and receiving additional adjuvant treatments. 
Two randomized controlled studies have indicated that axillary evacuation could be 
replaced by either follow-up or radiation therapy (19,20). Hence, the role of preoperative 
axillary staging with US and image-guided biopsies is also changing and the future of 
radiological interventions is becoming uncertain. It seems that the primary tumour size will 
become the fundamental parameter with which to guide the treatment strategies of the 
axilla, therefore supplementing the role of accurate primary diagnostics. Moreover, more 
accurate non-invasive or minimally invasive tools for axillary staging have become even 
more attractive. 
This doctoral thesis focuses on how preoperative radiological tools can be exploited in 
axillary staging; the tools examined were US-guided percutaneous biopsies and the more 
recently developed imaging modalities; magnetic resonance diffusion weighted imaging 
(MR DWI) and ultrasound contrast-labeling of the sentinel lymph node followed by 
percutaneous core biopsy (CB). 
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2 Review of Literature 
2.1 BREAST IMAGING 
The golden standard for the evaluation of breast diseases is the triple assessment which 
involves clinical, radiological and histological examinations. The radiological assessment 
comprises mammography (MGR) and ultrasound (US) for all breast cancer patients. 
Additional modalities include digital breast tomosynthesis (DBT) and magnetic resonance 
imaging (MRI). The BI-RADS lexicon was published in 1980 – 90’s to aid the interpretation 
and reporting of breast findings; this nowadays includes the MGR-, US- and MRI-features 
as well as listing the appropriate management of different breast findings (21). The latest 
update became available in 2014 (22). 
 
2.1.1 Mammogram, BI-RADS classification and tomosynthesis 
After the invention of X-ray imaging in 1895 by W.C. Roentgen, 18 years later MGR was 
introduced to breast cancer diagnostics in Germany by the surgeon A. Solomon (23). Since 
then the techniques, patient positioning and interpretation have changed dramatically. The 
screening programmes started in the 1970’s in Sweden; the first randomized trial 
investigating the benefit for MGR screening was published in 1985 and revealed a 31.0 % 
reduction in mortality (24). In Finland the national screening started in the late 1980’s and 
since 1992 it has been a compulsory health service to be provided by municipalities.  
In MGR screening, two images are obtained: craniocaudal and mediolateral oblique 
view. In symptomatic breasts additional views (lateral and possible spot, magnification or 
rolled views) are required. MGR has a wide range of sensitivity with respect to its ability to 
detect breast cancer (34.0 – 81.0 %) depending on the cancer histology and breast density 
(25). Its essential benefit is its high sensitivity to detect microcalcifications and the 
possibility to take stereotactic biopsies from calcifications. The overlapping of tissues and 
the density of the breast significantly decrease the sensitivity of MGR. On the other hand, 
recent data suggests that the masking effect of dense breasts can be markedly reduced by 
exploiting digital MGR rather than film-screen MGR (26). Digital MGR was introduced in 
1991 as a potential tool for breast cancer management (27). The mammographic breast 
density has been a topic of interest, not only due to parenchymal masking effect in MGR, 
but also because of the fact that women with dense breasts have a higher risk for 
developing breast cancer (28). Nevertheless, conflicting reports have been published on the 
effect of breast density to cancer survival outcomes; some report higher mortality with 
increasing density (29), while in a recent report with a Finnish patient population, a very 
low breast density ( < 10.0 % of dense breast tissue from the total area of the breast) was 
associated with a poorer prognosis (30).  
Whether as a part of screening, or with symptomatic patients, the evaluation of MGR 
always starts by determining the composition of the breast. The BI-RADS lexicon 
recommends that the breast density should be reported as follows; a) almost entirely fatty, 
b) scattered areas of fibroglandular tissue, c) heterogeneously dense breasts, in which small 
masses may be obscured, and d) extremely dense breasts, in which the sensitivity of MGR 
is decreased (Figure 1).  
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Figure 1. Mammography of four different patients to demontrate the differences in the 
mammographic breast density. According to the BI-RADS lexicon the classification is as follows; 
a) entirely fatty content, b) scattered areas of fibroglandular tissue, c) heterogeneously dense 
breasts and d) extremely dense breasts.  
 
The BI-RADS classification categorises lesions on a numeric scale of 0 - 6; 0 = incomplete 
evaluation, need for additional imaging/prior images, 1 = negative for malignancy, 2 = 
benign findings, 3 = probably benign, 4 = suspicious, 5 = highly suggestive of malignancy, 6 
= biopsy-proven cancer. All lesions categorised with a score over 3 require histological 
verification by biopsy. Category 3 should be subjected to short-term follow-up. The breast 
findings are categorised to masses, calcifications, architectural distortions and asymmetries, 
which all have specific subcategories to aid in the characterisation and to help estimate the 
probability of malignancy. There may be some additional findings in MGR which indicate 
that further investigations should be undertaken i.e. a solitary dilated duct, skin thickening 
or retraction, axillary adenopathy etc. (21,22).  
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The tumour histology in some cases represents characteristic findings in the MGR. The 
most common tumour type (75.0 %) is invasive ductal carcinoma (IDC), which typically 
exists as a spiculated mass on MGR. The second most common carcinoma (15.0 %) is 
invasive lobular carcinoma (ILC), which more often exhibits very subtle mammographic 
changes. The MGR can be totally normal (29.9 %) with ILC or more commonly there are 
signs of architectural distortion (13.8 %) or focal asymmetry (4.7 %) visual only in one view 
(34.9 %) (31).  
MGR, even digital MGR, have their limitations as described previously. To aid in the 
problem of superimposition of normal breast tissue in two-dimensional (2D) MGR, digital 
breast tomosynthesis (DBT) was developed. In this imaging modality, multiple low-dose X-
ray projections are acquired from the breast and three-dimensional images can be 
reconstructed. All traditional views of MGR can be obtained and from the DBT images a 
traditional 2D-image can be generated subsequently. There are several studies claiming that 
DBT reduces the need for additional views and spot compressions, hence decreasing the 
radiation dose. In addition, it minimises the impact of overlapping breast tissue and 
improves lesion conspicuity (32,33) as well as making it easier to detect architectural 
distortions and lesion margins (34,35). In the literature, the outcomes with DBT have 
demonstrated improved diagnostic performance figures both in clinical diagnostics and in 
screening (32,33,36). A recent meta-analysis (with seven studies and over 2000 patients) 
concluded that the sensitivity and specificity of DBT to detect malignancy was higher than 
digital MGR (90.0 vs 89.0 % and 79.0 vs 72.0 % respectively) (37). Nonetheless, more 
research will be needed to establish the role of DBT in clinical practice. 
  
2.1.2 Ultrasound imaging 
After MGR, US is the standard additional modality for breast imaging. In some cases, it 
may even be the first line approach, for example in symptomatic women < 30 years (38) and 
in screening high-risk patients (39). Since the invention of US in the 1950’s, the 
development of US techniques has been rapid and the role of US has increased, initially as a 
tool to characterise cystic breast lesions, but nowadays also to detect and analyse solid 
tumours (40). US is nonexpensive, easily conducted, and allows percutaneous biopsies 
without radiation exposure. The downsides are that it is performer and technology 
dependent and its accuracy to detect microcalfications is lower than MGR (41), though 
recent technical advances have increased the sensitivity (42). On the other hand, the breast 
US has benefits in terms of lesion detectability in dense breast tissue (43) and in ILC (31,44). 
In a retrospective analysis of 106 patients with ILC, breast US had a very low false negative 
rate in comparison to MGR (2.2 % vs. 29.9 %) (31). In another study with ILC patients (n = 
38), the sensitivity of MGR was 71.1 % compared to 89.5 % for US (44). 
The echogenic features for benign lesions are typically smooth borders, ellipsoid shape, 
gentle lobulations, thin capsule and homogenic echotexture (45). Similarly, for malignant 
lesions, high PPV and sensitivity have been found with the typical following features; 
spiculations, ill-defined borders, taller-than-wide shape, acoustic shadowing as well as 
small calcifications. These are the major US findings for malignancy described in the BI-
RADS classification (21,22). Imaging examples are presented in Figure 2. 
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Figure 2. Examples of different breast lesion charasteristics in US according to the BI-RADS 
classification. a) A homogenously hypoechoid, wider-than-tall lesion with smooth borders and 
posterior acoustic enhancement, a typical benign cyst. BI-RADS 2. b) A heterogenously 
hypoechoid, wider-than-tall lesion with multilobulated, mainly smooth borders and acoustic 
enhancement. Though having benign characteristics, the angulated border (arrow) is not 
acceptable and the lesion should be biopsied and categorised at least as a BI-RADS 4 lesion. 
The histopathology confirmed the presence of an aggressive invasive carcinoma. c) A taller-than 
wide, hypoechoid tumour intruding to normal parenchyma (BI-RADS 5) was proven IDC in the 
final histology. d) An ill-defined and spiculated, hypoechoid tumour with acoustic shadowing. A 
typical malignant lesion, BIRADS 5. e) An MGR negative palpable mass presenting only as an 
architectural distortion (between arrows) in US could be classified as BIRADS 4 or 5. Biopsy 
confirmed ILC. f) Calcifications in ductal carcinoma in situ. Calcifications (area between two 
arrows) can be very subtle or nonvisual in US and MGR is required for proper evaluation. 
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US is often repeated after breast MRI, which often produces new additional findings. It is 
not possible to biopsy all lesions in MRI-guidance due to its high cost and extensive time 
consumption. The so-called second-look US has been claimed to aid in the detection of 
small, malignant mass-lesions but cannot exclude malignancy if the lesion is not visible in 
the US (46).  
 
2.1.3 Contrast-enhanced ultrasound 
Contrast-enhanced ultrasound (CEUS), with intravenous injections of microbubble-
contrast, has been used for several years in abdominal and cardiac imaging (47). The use of 
CEUS has been incorporated into the recommendations and guidelines for good clinical 
practice in evaluation of liver lesions (48). Moreover, this technique has been utilised in the 
follow-up and detection of endoleaks after abdominal aortic aneurysm endografting, 
recently also with 3D-imaging (49). The US contrast available commercially in Finland, 
contains small sulphur hexafluoride gas particles (2.5 μm) that causes reflection of the US 
beam, hence its mechanism of action acts as an aid to visualise tissues with vascular 
structures or lesions within vascularised organs. The use of CEUS in breast radiology has 
been less popular in clinical practice. Nevertheless, in a recent meta-analysis of 31 studies, 
CEUS displayed good diagnostic properties in the characterisation of breast lesions (pooled 
sensitivity 86.0 % and specificity 79.0 %) (50). The clinical value in addition to breast MRI 
and traditional modalities, MGR and US, has not been validated. 
 
2.1.4 Needle sampling 
US-guided core biopsy (CB) is the standard biopsy method for solid breast lesions which 
demand histological proof (BI-RADS 4-5) (51-53). The minimum of four samples should be 
obtained from each solid tumour with a 14-gauge core needle (54). Similar results have 
been published with add-on stereotactic core biopsy with non-palpable breast lesions (55). 
Nowadays FNA is not recommended for breast tumours other than those with cystic 
consistency. It has also been proven to be more expensive than CB in Finnish patient 
population and health care system (n = 572) (56). 
Vacuum assisted biopsies (VAB), in which suction is applied in larger 9 - 11-gauge 
needles to remove larger tissue samples, have shown both better accuracy and cost-
effectiveness over surgical biopsies (57,58). The method is traditionally used in conjunction 
with stereotactic guidance since the 1990’s, but more recently it has been utilised also with 
MRI- and DBT-guidance. The latter approach was demonstrated to be significantly superior 
to traditional stereotactic-assisted biopsy in a recent retrospective study (DBT-guidance n = 
51, stereotactic-guidance n = 165) (59). Nonetheless, this retrospective analysis might have 
been subject to some possible bias, for example due to uncontrolled patient and lesion 
selection and the smaller number of patients examined with DBT-guided biopsy. 
Nevertheless, it is possible that DBT-guidance may help to decrease the number of lesions 
in MGR that are considered unsuitable for stereotactic VAB. 
The breast lesion excision system (BLES) is a new technique for tissue sampling and 
removal of small solid breast tumours. BLES biopsy and tissue removal are possible to 
perform with either US- or stereotactic-guidance. A publication from 2011 concluded that 
BLES biopsy is an efficacious technique in excising small indeterminate (BI-RADS 3) solid 
breast lesions (60). A complete margin could be achieved without the need for follow-up 
diagnostic surgery in the majority of patients and in 5-years’ follow-up the recurrence rate, 
with small high risk and low grade malignant lesions, was very low (60,61). Nevertheless, 
the studies have had small sample sizes and there is very little data concerning malignant 
lesions. Hence, the equipment is presently recommended only in sampling or removal of 
intermediate lesions.  
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2.1.5 Magnetic resonance imaging and diffusion weighted imaging 
MRI with gadolinium-contrast agent was introduced in breast imaging in the mid 1980’s 
(62). Breast MRI has the highest sensitivity (90.0 %) for detecting breast cancer, but it has 
been criticised for its low specificity (72.0 %) (63). In the 1990’s, after MRI technology 
developed to allow simultaneuous scanning, achieving high spatial and temporal 
resolution, the current so-called combined breast MR interpretation became favoured in 
breast imaging. This is based on the morphological criteria and dynamic enhancement 
pattern analysis of lesions. The latter includes dynamic contrast-enhanced T1-weighted 
images with fat saturation, where contrast intake and washout within lesions are imaged 
over time. The interpretation of the kinetics is divided into three type of curves (I = 
persistent, II = plateau, III = washout curve). In addition, the initial rise of the contrast 
intake is observed. First, the kinetics was emphasised and the type I curve was found more 
indicative of benignancy over malignancy (83.0 vs 8.9 %) where as type III was more 
frequent in malignancy (57.4 vs 5.5 %) (64). The importance of kinetic analysis, in the 
discrimination of benign and malignant lesions, has diminished with time e.g. a multicenter 
study revealed that the structural analysis of lesions possessed a higher accuracy (65). 
However this study also found evidence that the type III enhancement pattern was more 
common in malignancy (76.0 vs 45.0 %) but nonetheless the type I curve also is displayed in 
a significant number of malignancies (24.0 %) and this should be taken into account during 
MR analysis. There are four BI-RADS MRI classification’s descriptors which associate most 
strongly to malignancy; lesion shape, margin, heterogeneous enhancement and type III 
(wash-out) kinetics (66). 
It has proved difficult to undertake a reliable comparison between different studies with 
respect to the accuracy of breast MRI due to a lack of stardardisation of this imaging 
modality i.e. variable imaging protocols, scanning planes, as well as indications for imaging 
and interpretations of finding’s have been used in different centers (67). Subsequently, it 
has been proposed that there should be standardisation of the breast MRI indications and 
acquisition protocols, as well as in the interpretation and reporting in European guidelines 
for breast MRI (68,69). The guidelines also list the requirements for centers performing 
breast MRI, such as high technical quality, standard protocols and sequences. In addition, 
the possibility to perform MRI-guided biopsies should be available as well as established 
standard for reporting MRI findings such as the BI-RADS classification (68).  
Regardless of breast MRI’s high performance figures, its use in preoperative routine with 
invasive carcinoma has been disputed. A randomized control trial (COMICE), involving 
1623 patients, did not reveal any benefit in terms of a reduction in the reoperation rate for 
MRI over traditional triple assessment (70). Another randomized study (MONET, n = 418) 
detected a higher reoperation rate for MRI (45.0 vs 28.0 %) (71). On the other hand, in a 
recent publication (POMB trial, n = 440), preoperative MRI altered the treatment plans in 
18.0 % of patients < 56 years old and the reoperation rate was considerably reduced with 
MRI (72). 
According to the EUSOMA guidelines breast MRI should not be offered to all breast 
cancer patients, but it should be used as a problemsolver and used in certain patient groups 
where the advantage of MR has been established by high quality research (69). According 
to the guideline breast MRI should be used in the following situations; 1.) in the 
preoperative evaluation of patients presenting ILC in their breast biopsy result; 2.) in the 
search for unknown primary cancer; 3.) for symptomatic breast implants; 4.) in a 
preoperative evaluation when there exists a > 1.0 cm tumour size discrepancy between US 
and MGR in breast cancer patients < 60 years of age (69,73). Furthermore, it is well 
established that breast MRI should be used in screening of high risk patients (39,74). 
The diagnostic performance figures for breast MRI to detect malignancy have been 
reported to increase with higher field strength and stardardisation of imaging as well as 
standardised reporting. The 3.0T breast MRI achieves higher signal-to-noise ratios, higher 
spatial resolution, and faster scans than 1.5T MR, resulting in improved anatomical details 
9 
 
(75). In a recent study, the diagnostic figures for 3.0T breast MRI were 99.0 %, 81.0 %, 93.0 % 
for sensitivity, specificity and accuracy, respectively (66). 
Attempts have been made to overcome subjective variations in result interpretation e.g 
new quantitative functional methods have been introduced also into breast imaging such as 
magnetic resonance spectroscopy (MRS) and diffusion weighted imaging (DWI). MRS is a 
noninvasive method which analyses the tissue’s biochemical properties, in more detail the 
presence of choline metabolites (choline phosphocholine and glycerophosphocholine), 
which have been found to be elevated in cancerous tissues including breast cancer (76). In a 
meta-analysis for 1.5T and 3.0T MRS, the diagnostic values were 88.0 % for sensitivity and 
73.0 % for specificity (77). 
Of the two methods, DWI has become more popular and nowadays is often included in 
the imaging protocols (78). DWI detects the free movement of water molecules (Brownian 
motion). The apparent diffusion coefficient (ADC) values are calculated from DWI (with at 
least two different b-values) and displayed as a parametric map (Figure 3). If there is a 
malignancy, this causes a lower portion of freely moving water molecules and hence lower 
ADC values. This approach is applicable also in breast imaging (79-82). A meta-analysis 
conducted in 2010 (with 13 studies, 964 lesions; 615 malignant and 349 benign) reported the 
diagnostic performance of breast DWI to have pooled sensitivity of 84.0 % and specificity of 
79.0 % (83). However, there are limitations that should be acknowledged with DWI in 
clinical practice; the technique is not yet standardised and the reported cut-off ADC values 
for malignancy widely differ between reports. Moreover, ADC values are dependent on the 
b-values used during acquisition (84). The optimal b-values for DWI have been suggested 
to be 0 and 850 s/mm2 for breast imaging with 3.0T equipment (85). The higher field 
strength is a benefit also in DWI; compared to 1.5T, DWI at 3.0T was more accurate in 
detecting small cancers less than 1.0 cm (86). 
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Figure 3. Breast MGR and MR images of a 41-year old woman with 3.0 cm BI-RADS 5 breast 
tumour on the upper outer quadrant of the right breast (a,b,d,e). Additional 4.0 cm segmental 
non-mass enhancement was present in contrast-enhanced MRI, in the upper medial quadrant 
(between arrows) (c). The breast tumour was non-hemorrhagic and a necrotic center was 
visible on the contrast-enhanced T1 fat-saturated image (b). This can also be seen in the DWI 
image (b=800) (d) and in the ADC map (e). The ADC values obtained from the vital tumour 
area, avoiding central necrosis, were 0.620 – 0.795 x 10-3mm/sec2 (b-values 0,200, 400, 600 
and 800 at 3.0T field strength). At final histology, after mastectomy, there was a T2N1(mic) 
ductal carcinoma grade 3 with an extensive noncalcified DCIS-component, which was not visible 
in MGR (a) but was present in contrast-enhanced MRI (c). 
 
2.2 AXILLARY STAGING 
 
Axillary nodal status remains an important prognostic factor for invasive breast cancer 
(2,3,87). Around 13.3 - 21.0 % of patients with small breast tumours (< 1.0 cm) have axillary 
metastases and the probability increases with increasing size of the primary tumour (88,89). 
A tumour size of between 1.0 - 2.0 cm leads to around a 28.5 % probability of axillary 
metastases whereas half of patients (50.2 %) with tumours > 5.0 cm have axillary 
involvement (88). The reported values were similar in a Finnish study (10). In addition to 
tumour size ( > 1.0 cm), young age, multifocality or multicentricity, non-luminal A-type 
cancer and the presence of lymphovascular invasion increase the probability of axillary 
involvement (90,91). 
 
2.2.1 Breast lymphatics and lymph node anatomy 
The axillary anatomy includes the axillary artery and vein, brachial plexus, fat and LNs. 
The superior boundary includes the clavicle, scapula and first rib. The posterior boundary 
includes muscles (subsclapularis, teres major, latissimus dorsi). Medially there are first four 
ribs and serratus anterior muscle, laterally coracobrachialis muscle and short head of 
biceps. The regional LNs are divided into three levels i.e. level I (low axillary) = LNs 
laterally and inferior to pectoralis minor muscle, level II (mid-axillary) = LNs beneath 
e
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pectoralis minor muscle and the interpectoral (Rotter’s) LNs and level III (apical axillary) = 
LNs medial to pectoralis minor muscle and inferior to clavicle (Figure 4). Axillary LN 
metastases of breast cancer tend to spread step by step from level I to level II, from level II 
to level III and from level III to the internal jugular and/or supraclavicular nodes. Only 
rarely does metastasis proceed directly to level II or III nodes (92). Nevertheless, after 
axillary surgery the levels II-III, as well as parasternal LNs, should be included in the US 
follow-up evaluation of high risk patient.    
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The anatomy of the regional lymph nodes of the breast; 1. level I, the low axillary 
LNs, 2. level II, LNs beneath the pectoralis minor muscle, 3. level III, LNs medial to the 
pectoralis muscle and under the clavicle, 4. the supraclavicular LNs, 5. parasternal LNs, 6. and 
7. brachiocephalic vein and artery. 
The anatomy of the lymphatic system of the breast has been studied for several centuries 
and there have been several controversies about its lymphatic network. One theory which 
was proposed in the 1800’s was that the lymphatics of the whole breast routed through the 
subareolar plexus (plexus of Sappey) and then to the axilla. Nowadays, the favoured theory 
is that lymph drainage from the breast occurs to axillary LNs at a number of different sites 
and the axilla is only the main basin for lymph drainage (93). Two main lymphatic drainage 
routes are recognised; a superficial and an internal system (94). The superficial route 
collects lymphatics from the nipple, skin, and the lactiferous tubules and runs to the axilla, 
whereas the internal lymphatics arise from the breast lobules, leave the posterior surface of 
the breast, and pass through the pectoral and intercostal muscles to reach the internal 
mammary chain (Figure 5) (93). The smaller lymphatic capillaries drain into collecting 
lymphatic vessels and the lymph flow is maintained by a delicate balance between the 
pressures inside and outside the lymphatic vessel, which in turn drain into the axillary LNs. 
The drainage speed and the sentinel visualisation can be affected by age, disrupture of 
lymphatic network (i.e.by trauma or surgical operation), by injection site and volume and 
size of the particles in the used injection material. A gentle massage of the injection site has 
improved visualisation of the SLNs in the traditional sentinel procedure with isotope-
injection. 
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Figure 5. The anatomy of the lymphatic drainage system of the breast. 1. the mamilla, 2. 
subareoalar plexus (Sappey’s plexus), 3. breast lobule, 4. internal lymphatic network, 5. 
intramammary lymph node, 6. internal mammary chain lymph node, 7. superficial lymphatic 
network, 8. axillary lymph nodes. 9. pectoralis major muscle, 10. pectoralis minor muscle, 11. 
breast tumour. 
Lymph drainage enters the LN via four or five afferent lymph vessels, from there it 
continues to flow through the subcapsular and cortical sinuses in the cortex, which shows a 
typically hypoechoic image in axillary US. The lymph flow enters the medullary sinus and 
finally to the efferent vessel (Figure 6a). The inner parts of LNs appear hyperechoic due to 
hilar fat and blood vessels. The cancerous cells first locate in the subcapsular/cortical region 
where the percutaneous biopsy should be targeted (Figure 6b). 
 
Figure 6. The anatomy of the lymph node (a); A=afferent lymph vessel, B=lymphoid follicles, 
C=paracortex, D=germinal center, E=medullary sinus with fatty content and blood vessels, 
F=efferent lymph vessel, G=vein, H=artery, I=cortical and marginal sinus. b) A small 
metastatic deposit (J) in the cortex leading to local cortical thickening and lobulation which may 
be the first sign of metastasis in the axillary US.   
 
In some cases the cancerous cells grow through the LN capsule into the adjacent soft 
tissue which is called the extracapsular extension (ECE). ECE relates to increased local and 
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distant recurrences and is a prognostic indicator of survival (95). Moreover, ECE and its 
extent have been found to associate with higher axillary tumour burden in T1 - T2 cancers 
(96). In addition to the number of affected LNs and ECE, there are several lymph node-
related pathologic features which are believed to have prognostic value; nodal matting, 
nodal necrosis and the detection of tumour emboli within the extranodal vasculature (97). 
2.2.2 Axillary evacuation  
Traditionally axillary staging was done by palpation but this has proved to be inaccurate in 
at least 40.0 % of patients (98). For many years radical mastectomy and axillary clearance 
was the standard care for all sizes of breast cancers. Gradually less invasive surgical 
methods for axillary staging have proved to be adequate, as demonstrated in several 
randomized controlled trials (13,99-101). At present axillary lymph node dissection (ALND) 
includes removal of axillary LNs from level I and II. Level III LNs are removed in the case 
when the LNs in the lower levels are clearly pathological. The evacuation preparate should 
include a minimum of ten LNs for accurate pathological TNM staging (102). Axillary 
evacuation still has an important role when the sentinel procedure is not possible or fails to 
show any isotope-labelled LNs. 
The desire to avoid ALND is due to its long-term side-effects. In a Finnish 3-year 
surveilance study (n = 92) many patients suffered from axillary area pain (30.0 %), sensory 
disorders (66.0 %), lymphedema (13.0%) and shoulder motion restrictions (34.0 %) (103). 
According to objective measurements, after ALND lymphedema was detected in 16.0 % of 
patients. There were several risk factors associated with the development of these 
symptoms; greater body weight, infection or injury of ipsilateral arm (104). The majority of 
patients (40.0 - 60.0 %) with a positive SLNB in fact do not have any additional metastatic 
LNs in the evacuation (105), hence these patients suffer from possible adverse effects 
without gaining any benefits from the procedure. 
2.2.3 Sentinel lymph node biopsy 
Sentinel lymph node biopsy (SLNB) became rapidly the new golden standard for axillary 
staging in the 1990’s (13,99). It is an accurate procedure with high sensitivity (97.0 - 98.0 %) 
(100,101) and it saves majority of patients (60.0 %) from having to undergo unnecessary 
axillary evacuation when SLNB is negative (106). Increasing number of positive SLNs and 
increasing size of the largest SLN metastasis have been found to relate significantly to non-
sentinel node metastases (107). Less aggressive axillary surgery, SLNB, is beneficial 
resulting in less arm stiffness, pain, paraesthesia, and reducing the risk of lymphedema as 
described in the previous chapter (101,108). Nonetheless some patients (5.0 %) develop 
lymphedema even after SLNB as shown in a prospective study with 600 patients (109). 
Interestingly, there was no correlation between the number of LNs removed and the 
incidence of lymphedema. The authors postulated that other factors, such as the global 
disruption of the lymphatic vessels during ALND, may have a primary role in 
development of lymphedema rather than the number of LNs removed. 
The SLNB procedure is usually performed as a 1 - 2 day protocol and triple assessment is 
recommended; isotope-labelling with lymphoscintigraphy, hand-used gammadetector 
intraoperatively as well as blue dye injections which are is injected just before the 
operation. A few hours before the lymphoscintigraphy, the isotope is usually injected 
subdermally and para-areolarly to the cancerous breast, usually in the upper outer 
quadrant. Although the optimal injection site has been a matter of debate (110). According 
to the European guideline the sub- or intradermal injections should be used and 
intratumoral injections are not recommended due to lack of evidence (111). Peritumoral 
injection can be used when the tumour is located deeper in the breast tissue but in all other 
cases, it is recommended to deliver the sub-dermal injection over tumour site (111). With 
deep injections, it is believed that a significantly greater amount of extra-axillary SLN may 
be identified, but the clinical significance of this finding remains undetermined (110). The 
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SLNB procedure is not recommended with inflammatory breast carcinoma and the use of 
blue dye may be restricted by pregnancy or allergy. 
During SLNB procedure the radioactive and stained SLNs as well as all palpable 
suspicious LNs are removed by the surgeon and sent to pathology as a frozen section. This 
means that the SLNs can be evaluated intraoperatively. If a macrometastasis (> 2.0 mm) is 
present in the frozen sections, the practice has been to proceed to ALND. Later, after the 
final immunohistochemical staining, the presence of additional micrometastases (0.2 – 2.0 
mm) can be analysed. Frozen sections are not utilised in all breast surgery centers 
throughout the world and the SLNs may be analysed after primary surgery; in these cases 
ALND has to be performed as a second operation. The aim in many centers has been to 
avoid these secondary operations by conducting preoperative staging. Currently, also in 
Finland, the presence of micrometastases does not necessarily mean that the patient will be 
subjected to an additional axillary operation. Similarly the isolated tumour cells (ITC) 
visible in the SLNs are not considered to have clinical relevance. Moreover, the need for 
routine immunohistochemical staining of SLN has been questioned and practices have 
changed internationally due to its minimal advantage in local, regional or distant 
recurrence (112). 
Recently the need for routine axillary evacuation for all breast cancer patients has been 
debated. The result of prospective randomized controlled trial, ACOSOG-Z0011, were 
published in 2011; in that trial, patients with T1 - T2 sentinel node positive breast cancers 
were randomized to ALND or observation after SLNB. All patients received breast-
conserving surgery and whole breast irradiation including the axillary tail area. Patients 
with at least 3 positive sentinel nodes and patients receiving neoadjuvant chemotherapy 
were excluded from the study. After 6.3 years of follow-up there was no difference between 
the two study groups in the 5-year locoregional recurrence rate (4.1 % vs. 2.8 %), 5-year 
overall survival rate (91.9 % vs. 92.5 %), and 5-year disease free survival rate (82.2 % vs. 83.8 
%) (19). Hence the authors concluded that ALND could be avoided in selected patients who 
meet the Z0011 study criteria. Another randomized trial (AMAROS) included patients with 
breast tumours < 5.0 cm and clinically node negative axillae. In this trial, the axillary 
positive patients (no upper limit for metastatic sentinel LNs) were randomized to ALND or 
radiotherapy with similar results; no difference between the two groups (20). Though 
having fairly short follow-up times (6.1 years in AMAROS and 6.3 years in ACOSOG), the 
results of these trials have changed the treatment of the axilla in the most enthusiastic 
centers in the States. Nevertheless, the ACOSOG-trial has attracted considerable criticism 
and the results have been questioned due to several reasons, for example; a significant 
portion of patients were lost from follow-up and the numbers of micrometastases were 
overrepresented. Furthermore, the radiation fields were not standardised and there were 
protocol violations (113). From the radiologist’s point of view, there is only limited 
information available on the preoperative axillary investigations for the included or 
excluded patients. One could speculate that some patients probably had preoperative 
investigations and biopsies since the micrometastases were overrepresented. The AMAROS 
trial has been better received by the international research community and it has stated that 
preoperative investigations were performed on 60.0 % patients. Nevertheless, the detailed 
information of the preoperative investigations and the possible exclusion of patients due to 
positive findings, are missing (20). 
The role of preoperative US and biopsies is inevitably being challenged by new emerging 
evidence. Some, mainly American centers, have omitted the preoperative investigations but 
in Europe, the approach has been much more cautious. On the other hand, it is recognised 
that there has been over-treatment of the axilla in small breast cancers, and even the need 
for SLNB has been questioned. Two new randomized trials have started in Europe, which 
are randomizing patients to either SLNB (proceeding to ALND if necessary) or surveillance 
(SOUND, INSEMA) (114,115). The inclusion criteria in these trials involve the size of the 
primary tumour i.e 2.0 - 5.0 cm and the axilla should be clinically or US negative. In 
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addition, the biopsy (FNA, CB) negative axillae are included. The trials’ goals are to 
investigate if observation after partial breast surgery treatments will suffice and whether all 
surgical axillary procedures can be avoided in these patient groups. 
 
 
2.3 IMAGING OF THE AXILLA 
 
The presence of axillary metastases can be evaluated with several imaging modalities. MGR 
has been the traditional and basic tool for visualising breast lesions and it can be used to 
screen for axillary metastases, but with low accuracy. Axillary US has been the most 
utilized modality in clinical practice. Its benefits are its widespread availability, low cost, 
patient comfort and avoidance of ionizing radiation. Moreover, its absolute advantage over 
other modalities is the possibility to take accurately image-guided samples from the axillary 
LNs.  
MRI is used frequently to assess breast malignancies preoperatively as described 
previously. At least the lower parts of the axilla are visualised in the traditional breast MRI 
sequences, hence the evaluation of the axillary LNs by MRI does not necessarily demand 
any additional resource utility i.e time or cost. Nonetheless, it is neither possible nor 
recommended to use MRI in all breast cancer patients due to its high cost, time-consume 
and additional incidental findings. Moreover, the number of available axillary LN MRI 
studies is small and they have employed variable methods; therefore, their results need to 
be interpreted with caution (116).  
Although accurate in the detection of distant metastases, the positron emission 
tomography (PET) has clear limitations in axillary staging. According to a meta-analysis, 
the diagnostic performance values for PET or PET-CT vary widely between studies 
(sensitivity and specificity between 20 – 100 % and 75 – 100 %) and presently it cannot be 
recommended in the preoparative staging in newly diagnosed breast cancer (117). There 
are several factors limiting its wider clinical use; for example the high cost, limited 
availability and most importantly the patient’s radiation exposure. 
2.3.1 Mammogram 
In the MGR’s lateral oblique projection the axillary tail area should be visualised and often 
axillary LNs are present and available for evaluation, at least to some extent (Figures 1d and 
3a). Nonetheless, the majority of the studies do not include visual LNs even in the properly 
positioned lateral oblique projections (Figures 1a-c). The normal appearance of a benign LN 
in MGR is typically a bean shaped structure with a visible dense cortex and lucent hilum 
with a fatty content. They can also appear as dense oval or round masses depending on the 
direction of the X-ray beam and hence appear rounded and enlarged even though they are 
benign. On the other hand, even small LNs and LNs with a marginally enlarged cortex can 
have metastatic deposit. Therefore, in most cases benign and malignant LNs cannot be 
distinguished from each other by MGR (118). The sensitivity of palpation and MGR are 
both significantly lower than US (38.9 % and 32.3 % vs 72.7 %) (119). Nevertheless, the 
appearance of the LNs should always be monitored during an MGR evaluation and an 
increased size or density of LNs should raise concerns about possible pathology. Unilateral 
adenopathy in MGR can be a suspicious finding for ipsilateral breast cancer, whereas 
bilateral enlarged LNs may originate from several reasons e.g. reactive hyperplasia or 
rheumatoid arthritis or in rare cases non-breast related malignancy, for example lymphoma 
or leukemia (120). 
2.3.2 Ultrasound imaging 
Preoperative axillary US is widely used in the clinical evaluation of newly diagnosed breast 
cancer patients and is included in the national guidelines (53,121). Axillary US evaluation 
has been shown to increase the sensitivity to detect LN metastasis over clinical palpation 
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(15). The sensitivity of axillary US, reported in the three available meta-analysis, has varied 
between 61.0 – 62.0 % with 82.0 – 86.0 % specificity (122-124). The diagnostic accuracy is 
dependent on the threshold criteria for the suspected malignancy (125-128). Several 
different criteria for malignancy have been investigated. The following morphological 
features of axillary LNs; the absence of fatty hilum, multilobulated cortex and increasing 
nodal size, have been found to be independent predictors for metastasis (124,129,130). In 
addition, peripheral/cortical blood flow was significantly associated with malignant (77.0 
%) compared to benign (28.0 %) LNs in a prospective study with 145 LNs (p = 0.001) (131).  
As the US techniques advance and the image quality improves, even smaller details in 
LN’s morphology can be investigated more intensively. The concept of ECE has appeared 
in radiological publications. Certain US features such as unclear margins, node matting, 
perinodal edema and hilar replacement have a statistically significant association with 
histological ECE. The first three features predicted ECE with high specificity (75.0%, 84.0%, 
87.0%, respectively) (132). Nevertheless, none of these criteria have increased the diagnostic 
performance of axillary US enough to decide on surgical treatment of the axilla, especially 
to omit SLNB and triage patients directly to ALND.  
After the publications of ACOSOG- and AMAROS-trials, the consept of axillary tumour 
burden rapidly became popular in the literature concerning preoperative staging. Most of 
the publications refer to axillae with < 2 positive (macrometastases) LNs as low tumour 
burden and > 3 positive LNs as high burden. Several retrospective publications with 
preoperative US and biopsies in the evaluation of axillary tumour burden have appeared in 
the literature (124,133-137). The axillary US-positivity has been found to relate to less 
favorable disease characteristics and a worse prognosis than SLNB-positivity (136). 
Moreover, the US-guided FNA-positivity has been noted to significantly associate to a 
higher axillary tumour burden accordingly; > 3 positive LNs in 63.3 % of FNA-positive 
patients vs. 22.7 % of SLNB-positive patients (p < 0.001) (136) and > 2 positive LNs in 61.0 % 
of FNA positive patients in a second study (136,138). Axillary US with FNA had NPV of 
99.0% for higher tumour burden with a sensitivity of 91.0 % in a study including 139 
patients with T1-T2 breast tumours undergoing breast conserving surgery (134). In 
addition, in a retrospective analysis preoperative axillary US excluded 96.0 % of patients 
with N2 and N3-disease (139). Moreover, a single nodal metastasis, detected by axillary US 
biopsy (with cortical thickness limit > 3.0 mm), correlated with a mean of 5.2 positive LNs 
in the final histology (135). The authors concluded that axillary US and biopsies most likely 
will remain valuable tools in guiding the management of the axilla in breast cancer in the 
future. Similar results have been obtained in a Finnish retrospective study, in which the 
patient population was analysed according to the ACOSOG trial’s inclusion criteria (140). 
In that analysis, none of the axillary US negative axillae (40.1 %, 73/182) had a higher 
tumour burden.  
2.3.3 Needle sampling 
The sensitivity and specificity of axillary US can be further increased by US-guided axillary 
needle biopsies. In addition, axillary biopsy has been assessed as being more cost-effective 
when the SLNB procedure can be omitted based on a positive biopsy result (141,142). LN 
biopsies are nowadays generally used as a preoperative investigation for breast cancer 
staging in major breast clinics and are included within the national guidelines (53,121). 
Axillary US-guided LN biopsies have been performed with either FNA or CB (122-124). US-
guided interventions have increased the detection rate of definite LN metastasis with 
perfect specificity of 100 % (15,125). The sensitivity values in the literature vary greatly 
between 21.0 - 86.0 % for FNA (143,144) and 42.0 - 94.0 % for CB with 100 % specificity 
(126,130,145-155). In the three available meta-analysis for axillary biopsies with any size of 
needle, the sensitivities of axillary biopsy varied between 49.0 - 87.0 % (122) and 79.0 - 80.0 
% (123,124) with 100 % specificity. In a recent meta-analysis for axillary FNA studies (n = 
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31), the sensitivity was 63.0 % and spesificity of 99.0 % (156). No meta-analysis exists with 
respect to axillary CB. The literature of existing CB studies is presented in Table 1.  
The sensitivity for FNA has been highest in the centers where the cytopathologist is 
available at the time of the procedure to ensure the adequacy of the samples. This is not 
possible in the majority of the centers and in none of the Finnish hospitals. In Kuopio 
University Hospital, for several years the clinical practice has been to perform axillary 
sampling with CB. Nevertheless, the absolute superiority of CB over FNA in axillary biopsy 
had not been established since there were no prospective trials comparing the two 
techniques at the beginning of this thesis (153).  
The specificity of needle biopsies is affected by the criteria for axillary sampling which 
differ greatly between breast centers and published studies. Although there is a consensus 
on the biopsy of morphologically suspicious LNs, the detailed thresholds such as the LNs’ 
cortical thickness, are still disputed. The maximum cortical thickness of LNs has been 
speculated to be a good predictor of metastatic involvement and the cut-off point of 2.3 mm 
as the diagnostic criterion for pathology, produced a sensitivity of 95.0 % but with low 
specificity of 44.0 % using FNA sampling (127). Sensitivity of 85.0 % and higher specificity 
(78.0 %) were associated with the cortical thickness threshold of > 2.5 mm in a study with 
US wire-localization (157). There are two different measures for LN’s cortical thickness in 
national guidelines in the literature; 2.0 mm and 3.0 mm (121,158). The first is adopted also 
into present Finnish recommendations with additional criteria for axillary LN biopsy as 
follows; lobulated or eccentric cortex, any eccentric or concentric thickening greater than 2.0 
mm, dislocated and/or absent fatty hilum, a cortex-to-hilum ratio greater than one, or a 
longitudinal axis–to–transverse axis ratio less than two (Figure 7) (121). On the other hand, a 
recent American recommendation has utilized a cortical thickening of 3.0mm as an 
indication for axillary biopsy (158). 
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Figure 7. Examples of morphological features indicating axillary LN biopsy; a) local eccentric 
cortical thickening > 2.0 mm, b) multilobulated cortex, c) smooth cortical thickening > 2.0 mm 
with cortical blood flow, d) dislocated and/or absent fatty hilum. 
2.3.4 Contrast-enhanced ultrasound 
Additional applications for CEUS in oncological imaging and the localisation of SLN are 
being investigated. An intravenously administered US microbubble contrast has been used 
in a limited number of preliminary studies concerning detection of metastasis, for example 
in the cervical region from thyroid cancer or other head and neck-malignancies (159,160). 
This approach has also been utilised in axillary staging and in the prediction of tumour 
aggressiveness in patients with breast cancer (161-163). These preliminary studies found 
that this technique with the intravenous contrast injections had very limited clinical value 
in axillary staging. On the contrary, a sentinel procedure with contrast injections into the 
the para-areolar skin of the breast has shown promising results and applicability in clinical 
practice in visualising the lymphatics. The first CEUS sentinel procedure was published in 
2004 in a swine-melanoma model (164). With breast cancer patients, the skin injection of US 
contrast was first introduced in 2009 (165). Since then, a limited number of publications 
have appeared evaluating this procedure, although they mainly originate from the single 
institution that first described the method. In CEUS sentinel the microbubble contrast is 
used in a similar manner as isotope injections in the traditional SLNB procedure. The 
contrast is injected into the skin of the breast para-areolarly and the drainage of the contrast 
can be immediately followed in realtime US to the lymph vessels and further to axillary 
LNs (Figure 8) (166,167). 
The sentinel localisation with CEUS has high sensitivity (89.0 - 93.0 %) to detect axillary 
SLN (166,168). At present, there is only one additional study from another center and with 
different type of US contrast, containing perfluorobutane microbubbles, which are reported 
to stay visible for a longer time. This trial examined 20 patients and reported a 70.0 % SLN 
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detection rate for CEUS in comparison to blue dye and gamma-probe (75.0 % and 100 %, 
respectively) (169). Marking of CEUS SLN has also been topic of investigation. In the 
literature, CEUS has been used to guide LN marking with guidewires just prior to the 
operation (166) and, in a more recent study, with a radioactive seed (I-125) (170).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Axillary US images (a-c) of a 49-year old woman with an upper lateral carcinoma in 
the left breast. (a) In the CEUS procedure, a fluent flow of US contrast is visible in a single 
lymph vessel (arrow head) heading to axillary LN (arrow). (b) Enhancements of two axillary LNs 
were present (arrow and double arrow). (c) The first LN to enhance (arrow) (a and b) had a 
cortical thickness of 2.5 mm in grey scale US and was biopsied with a true negative 
histopathology (T2N0M0). 
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2.3.5 Magnetic resonance imaging and diffusion weighted imaging 
Axillary LNs in level I are usually visible in traditionally positioned breast MRI and in most 
cases, some additional LNs from levels II - III. Since the SLN is often the lowest possible 
axillary LN (171) and is most likely to be affected, the use of simultaneous imaging and 
analysis of the axilla with breast MR and DWI is very attractive from a clinical point of 
view. The LNs are easily recognised from the axillary fat in anatomical T1- and contrast-
enhanced T1-fat saturated-sequences and well visualised in the DWI as high intensity 
lesions. The following morphological features of axillary LNs on MRI have been found to 
significantly associate with metastases; irregular margin, inhomogeneous cortex, perifocal 
edema and asymmetry (172). The reported mean sensitivity and specificity of basic MR 
techniques in detecting metastatic LNs are moderate and vary greatly between studies 
included in review articles (sensitivity of 88.0 % and specificity of 73.0 %) (116). These are 
studies based on morphological evaluation of the LNs. In conjunction with improving 
image quality and generalisation of DWI in breast MR imaging, also axillary staging with 
DWI and quantitative ADC measurements have been attempted recently and are being 
investigated intensively. 
There are a limited number of articles concerning the axillary DWI and the use of ADC 
values in the evaluation of breast cancer’s axillary metastases (173-179). Nevertheless, the 
studies seem to indicate that an axillary metastasis is significantly associated to decreasing 
ADC values paralleling the behaviour of ADC values with breast tumours and other 
malignancies. The studies currently available are reviewed in Table 2 and were mainly 
performed with 1.5T field strength. In the most recent studies, the higher field strength, 
3.0T, has been used and the axillary biopsies are also included.  
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The possible explanations for unsatisfactory diagnostic accuracy of DWI with axillary 
metastases may include partial volume effects since LNs are often relatively small 
(diameters less than 0.5 cm). Furthermore, not only metastasis, but other reasons such as 
reactive hyperplasia and fibrotic proliferation possibly affect diffusion and the ADC values. 
The inclusion of the minimum b value of 0 s/mm2 in ADC calculations and the use of 
monoexponential fit can lead to possible perfusion contamination from red blood cells 
moving in the small capillaries (78). 
In the evaluation of the ADC values, the hand drawn region of interest (ROI) based 
techniques have their own limitations such as ROI reproducibility and accuracy. In 
addition, the size of the ROI will affect the obtained ADC values. In a study concerning the 
optimal ROI size in DWI imaging and ADC analysis of breast lesions, a small sized ROI 
placed on the region of most restricted diffusion, was shown to be more accurate than a 
larger ROI covering the whole breast lesion (180). Nevertheless, it also remains difficult to 
correlate ROIs directly from anatomical images and contrast sequences, where lesions are 
best visualised, due to common distortions of the DWI causing shifts in the position (78). 
Semi-automated methods for performing a voxelwise analysis or reduced field of view-
techniques have shown promise for overcoming these challenges (80,181). Before these 
methods become commercially available, it would be advantageous if the recognition of 
LNs on ADC maps could be conducted with comparison to anatomical sequences with 
localisation tools in a work station. 
2.4 NEW TECHNIQUES FOR AXILLARY STAGING 
New imaging and combination techniques to stage the axilla have been described in the 
literature. The CEUS technique has been applied in animal models where the SLN has been 
percutaneously excised by using the Intact Breast Lesion Excision System (BLES, Intact 
Medical, Framingham, MA, USA) (182). Other new US techniques, such as elastography, 
have been investigated. US elastography is an imaging method utilising the long-
established clinical awareness that malignant lesions are often stiffer than the surrounding 
tissues. The sensitivity of elastography to detect LN metastases in breast cancer has been 
reported between 60.0 – 90.0 % with specificity between 79.6 – 89.0 % (183,184). The best 
specificity (99.3 %) was achieved by combining B-mode US with the elastogram (cortex 
thickness > 3.0 mm and blue cortex in visual elastogram), but with very low sensitivity (26.7 
%) (184).  
Some new MR techniques for breast imaging, which may be exploited later for axillary 
imaging, have been presented in the literature such as 7.0T imaging (185) and diffusion-
tensor imaging in preliminary studies (186,187). A few reports on MRS in the detection of 
axillary metastases can be found (188,189) with a reported sensitivity of 82.0 % to detect 
axillary metastases with addition of FNA (189).  
The highest diagnostic values for noninvasive imaging have been reported for ultrasmall 
superparamagnetic iron oxide (USPIO) -enhanced MRI. In this method, after intravenous 
injection of USPIO-contrast, the normal LNs accumulate iron-containing nanoparticles that 
reduce the nodal signal due to susceptibility effects, while metastatic LNs do not 
accumulate the nanoparticles and thus they continue to display a high signal intensity in T2 
or T2*-weighted images (190). USPIO-contrast has been added also to DWI in a preliminary 
study with 16 breast cancer patients and 286 LNs. In that study the sensitivity of USPIO-
MRI increased with DWI versus T1- / T2*-images (83.0 % vs 70.0 %) both having high 
specificities (98.0 %) (191). In a meta-analysis and review of MR assessment for axillary 
metastases in early stage breast cancer, the mean sensitivity for USPIO-MRI was stated as 
being 98.0 % with specificity of 96.0 % across five different studies. With respect to contrast-
enhanced MR, the corresponding values were 88.0 % and 73.0 % (116). 
New techniques for sentinel LN localisation during surgery have also been introduced 
such as magnetic tracers or indocyanine green tracers to overcome the disadvantages of 
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radioisotope and blue dye. In multicenter studies, the labeled sentinel LNs were identified 
either with a hand-held magnetom or with a fluorescence-based method and high detection 
rates were observed (192,193). In addition, attempts have been made to supplement the 
sentinel localisation with a combination of gamma probe and US-guided hook-wire 
placement with a high success rate of 92.0 % (35/38 patients) (194). 
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3 Aims of the Study 
The general aim of the study was to undertake a prospective investigation of new methods 
of preoperative imaging and image-guided interventions in staging axillary lymph node 
metastasis in newly diagnosed breast cancer patients. 
 
The more specific aims were:  
 
I To compare the diagnostic accuracy of ultrasound-guided fine-needle aspiration and 
core-needle biopsy of the axillary lymph nodes. 
 
II  To investigate the feasibility and diagnostic performance of magnetic diffusion 
weighted imaging at 3.0 Tesla in the detection of axillary metastasis in a clinical 
setting and to determine the accurate apparent diffusion coefficient values for 
histologically proven metastatic lymph nodes. 
 
III  To evaluate the feasibility and accuracy of contrast-enhanced ultrasound-guided core 
biopsy in the detection of axillary metastasis. 
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7 General Discussion 
7.1 STUDY I 
There are currently three prospective studies available which have conducted a comparison 
of axillary CB and FNA in axillary biopsy (154,155,212). In these publications, CB has 
displayed higher performance values than FNA; sensitivity of 88.0 % vs 73.0 % (study I), 
77.0 % vs 73.0 % (154) and 83.0 % vs 72.0 % (155), respectively. Nonetheless, the difference 
has not quite achieved statistical significance except in study I in this thesis (88.0 % vs 73.0 
%, p = 0.008). Furthermore, similar results with respect to sensitivity were found in a recent 
meta-analysis (83.0 % for CB vs 72.0 % for FNA) (124). While lacking statistical significance, 
the studies concluded that either needle could be used according to availability of the 
cytopathologist and accessability of the target LN (155) or recommended the FNA due to its 
minimal invasiveness and lower cost (154). The latter could be contradicted as described 
earlier in chapter 2.1.5 with breast tumours, at least in Finnish health care system (56). The 
comparative studies have also methodological limitations which might affect the results; 
one study used variable needle types and sizes as well as single to multiple passes in their 
subgroup analysis (155) and the other trial was limited by its small sample size and 
potential variability among the radiologists performing the procedures (154). In addition 
selection bias and the lack of standardised criteria for the patient populations were 
additional limitations reported.  
Interestingly, in addition to the aforementioned reasons in the previous chapters, the 
histology of the primary cancer has been reported to considerably influence the accuracy of 
preoperative radiological staging (139,220); this issue was not addressed in detail in this 
thesis and should receive more attention in the future. In a retrospective analysis from 2010, 
the preoperative US showed significantly higher false-negative rates in detecting N2 - N3 
axillary metastases from invasive lobular cancer (ILC) than invasive ductal carcinoma 
(IDC)(139). Similarly, a retrospectively study on axillary LN FNA reported more false 
negative biopsy results with ILC than IDC (false negative rate 46.4 % vs 1.6 %) (221). The 
difference was thought to arise from the different histology of these cancer types since the 
cells in the ILC nodal metastases are small and non-cohesive (222) and therefore more 
difficult to detect with cytology. Nonetheless, similar results have been found with CBs; in 
a prospective study with 142 patients, the sensitivity of axillary CB in ILC was 36.0 % vs 
76.0 % for all other cancer types (223).  
7.2 STUDY II 
In agreement with the results of study II in this thesis, decreased ADC values have been 
clearly associated with axillary malignancy in several other studies (173-179). The ADC 
values obtained are dependent on the maximum b-values used (85) and this introduces 
problems in the comparison of ADC values between different studies. In the literature, 
there are three studies with similar minimum and maximum b-values (0 and 800) as 
employed in study II in this thesis, and the ADC values for malignant LNs have varied 
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between 0.698 - 0.878 x 10-3mm2/s (174,176,178,224). Eventhough the sensitivity of DWI to 
detect metastasis was reported at best as perfect (100 %) in one study (177), but because it 
has lower than 100 % specificity (54.0 - 91.7 %), the method cannot be used in the treatment 
management in clinical breast cancer patients.  
The analysis of LNs has shown to be problematic due to several reasons, even without 
taking into account the variability and quality of DWI acquisition and interpretation. The 
cancerous LNs can be very small and the lack of histopathologic verification has been one 
problem. To overcome this issue, histological verification with US-guided needle biopsies 
and correlation with DWI has been performed also in some recent studies published almost 
simultaneously with study II in this thesis (178,179,224). The ADC values of histologically 
proven metastatic LNs seem to vary between 0.663 - 0.746 x 10-3mm2/s and are clearly lower 
than in the benign LNs (178,224). 
7.3 STUDY III 
In study III, the CEUS sentinel procedure made it possible to biopsy the actual first LNs 
draining lymphatics from the breast and this technique could detect all patients with higher 
axillary tumour burdens. The procedure could be performed without particular hands-on 
training and it was proved to be valuable.  However, before it can be introduced into 
clinical use, some limitations should be considered. The CEUS procedure has the same 
limitations as the isotope-injections as well as a restricted time-window related to the 
sustainability of the gas-bubbles in the contrast fluid. In some cases, there was no 
enhancement seen in the axilla and a decreased flow of contrast in the lymph channels. This 
could be related to known causes of failure in the traditional isotope-sentinel identification, 
such as increasing age and weight of the patient, as well as tumour-related reasons (size, 
location, palpability) (225). The CEUS injection cannot be injected subdermally or 
peritumorally, since the faster lymph flow in the superficial network is required in order to 
keep the bubbles intact and contrast visual in US.  
As new evidence emerges on the issue of axillary burden, the CEUS may acquire an 
additional role to screen out a higher axillary burden. Moreover, since the ACOSOG or 
AMAROS studies’ conclusions are not currently accepted in Finnish breast centers, CEUS 
CB could be used in all node negative cases until the role of axillary biopsies is finally 
resolved. The additional limitation of the CEUS-CB is that currently the majority of the 
axillary CEUS-sentinel publications are from single institution and the validation of the 
method in other institutions is scanty. Clearly the CEUS sentinel procedure needs to be 
examined more widely before it can gain acceptance for widespread clinical routine. Other 
oncological applications for contrast in sentinel procedure are under investigation, for 
example in melanoma, but with limited success in lymphatic enhancement (226). As 
experience grows and the procedure becomes more widely used around the world, also the 
enhancement type of LNs, flow of the contrast and 3D-contrast imaging may become topics 
of research.  
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7.4 GENERAL DISCUSSION, CLINICAL RELEVANCE AND FUTURE 
ASPECTS 
As many as 40.0 % of breast cancer patients have axillary lymph node metastases and 
preoperative staging screens about half of the patients directly to ALND. The trend and 
goal of recent randomized control trials (ACOSOG, AMAROS) have been to find 
compensatory treatments for the metastatic axillae (19,20). There are relevant questions i.e. 
whether the axillary evacuation is needed for all patients with a low axillary tumour 
burden, since the axilla is often treated with radiotherapy.  Rather surprisingly to for 
European clinicians, the American ASCO guideline already states that ALND should not be 
recommended for women with early-stage breast cancer who will have one or two sentinel 
lymph node metastases and will receive breast-conserving surgery with conventionally 
fractionated whole-breast radiotherapy (227). This approach is not accepted in European 
centers since the trials, on which the guideline was based have been heavily criticised, for 
example the follow-up time of these studies is considered to have been too short. In Finnish 
breast centers, the changes to clinical practice are applied more cautiously; currently the 
need for routine SLN frozen sections has been questioned and found unnecessary with 
unifocal small breast tumours (< 15.0 mm) and US negative axilla since any 
macrometastases are randomly found (140). In addition, the ALND is no longer justified 
with micrometastases in frozen sections (228).  
Within a few years, the role of axillary US and US-guided biopsies may change, when 
the results emerge from two European randomized control trials (SOUND and INSEMA) 
(114,115). It could be speculated, that the role of axillary US might increase after the results 
of these studies. Moreover, the criteria by which LNs are considered malignant in these 
trials, are to shed light on preoperative axillary interventions and may assist the creation of 
more uniform guidelines for axillary LN biopsies. The limit of 2.0 mm for cortical thickness 
according to NICE and national guidelines (53,121), was used in this thesis with good 
diagnostic figures but the limit might be too strict for small unifocal tumours (T1) and lead 
to excessive axillary biopsies since the axillary positivity in this patient population is low 
(26.5 %). 
The studies in this thesis have some limitations. The patient populations in each study 
are quite small. This is due to the size of our institute where only around 220 new breast 
cancer patients are operated each year. There were some factors in the inclusion criteria 
(preoperatively BI-RADS 5 and 6 lesions) that caused bias in each study concerning the 
axillary positivity. In study I, all new consecutive patients with confirmed invasive breast 
cancer in the preoperative breast biopsy were evaluated. Hence the axillary positivity (42.0 
%) was probably slightly overrepresented at least in small breast tumours. Moreover, due 
to the clinical breast MRI criteria, the axillary positivity (54.0 %) in patients in study II was 
clearly higher than in the normal patient population. The EUSOMA guideline (69) was 
utilised and there were more larger tumours and younger patients in this study. On the 
other hand, the inclusion criteria for axillary negativity in study III was very strict and the 
number of axillary metastasis was low (16.7 %). Hence, the possibility to conduct a 
subgroup analysis for tumour burden was quite limited.  
Finally, axillary staging of breast cancer is inevitably changing with current knowledge 
and the future role of axillary US and biopsies is uncertain. What one can predict is that the 
role of radiology will increase in the future as more accurate preoperative breast 
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diagnostics is required in the planning of treatment. This demand will be linked not only to 
the introduction of new surgical procedures of the breast but also with the refinement of 
preoperative axillary techniques in order to exclude with confidence the higher axillary 
tumour burden. 
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8 Conclusions 
I Since the accuracy of axillary US is increased with axillary lymph node needle biopsies 
and core biopsy, this procedure is recommended due to its higher sensitivity over fine-
needle aspiration. New and accurate non-invasive methods to stage the axilla in newly 
diagnosed invasive breast cancer are needed in this era of changing treatment strategies.  
 
II The diagnostic figures for DWI at the moment are moderate. Decreased ADC values 
associate strongly to metastasis in the axillary LNs. Standardisation of DWI techniques and 
interpretation is needed and currently the method cannot be used to substitute for SLNB or 
US-guided biopsies.  
 
III Contrast-enhanced ultrasound-guided percutaneous sentinel biopsy is a feasible 
intervention and it was able to exclude patients with a high axillary tumour burden. The 
coil marking approach cannot be recommended. More studies will be needed to validate 
the CEUS procedure and to identify the appropiate patient populations.   
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Axillary involvement is an important 
prognostic factor for breast cancer. 
This prospective study investigated 
the accuracy of preoperative tools in 
axillary staging; percutaneous needle 
biopsies, diffusion weighted imaging 
(DWI) and contrast-enhanced ultra-
sound (CEUS). This thesis revealed 
that core biopsy is more accurate 
than fine needle aspiration and it 
reduces the need for sentinel lymph 
node biopsy. Moreover, DWI and 
CEUS-guided biopsy, have moderate 
diagnostic properties but more stud-
ies will be needed before introducing 
these methods into routine clinical 
practice.
